Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E‐based antibody–drug conjugates

Documenti analoghi

• A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
  di: Jane Knöchel, et al.
  Pubblicazione: (2024)
• Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy
  di: Maike Scherf‐Clavel, et al.
  Pubblicazione: (2025)
• Physiologically based pharmacokinetic modelling of cefoperazone in paediatrics
  di: Qiushi Wang, et al.
  Pubblicazione: (2024)
• Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women
  di: William Saffaf, et al.
  Pubblicazione: (2026)
• Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study
  di: Amelie Leutzendorff, et al.
  Pubblicazione: (2024)